Myasthenia gravis (MG) tends to be more severe in people who are female, obese, or who took a long…
Articles by Marisa Wexler, MS
Immunovant will use a $200 million strategic investment from Roivant Sciences to advance IMVT-1401, its investigational therapy for…
A very rare case of a myasthenia gravis (MG) crisis caused by the Moderna COVID-19 vaccine was described recently…
Eurordis opened a campaign, called Rare 2030 Action, that is seeking to establish a European action plan for…
Following a review of available clinical data, Immunovant has announced plans to resume clinical testing of the investigational medication…
People with myasthenia gravis (MG) who have difficulty swallowing are more likely to have poor clinical outcomes, according to…
Editor’s note: The Myasthenia Gravis News team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April…
When used over long periods of time, Soliris (eculizumab) does not increase the risk of infections in people with…
The U.S. Food and Drug Administration (FDA) is now reviewing an application from Argenx that seeks approval of …
In a $3.05 billion deal, Horizon Therapeutics will acquire Viela Bio, the developer of inebilizumab, a potential treatment for autoimmune…